Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

HIV Drug Combo Possibly Fatal

By Drug Discovery Trends Editor | February 24, 2010

WASHINGTON (AP) – The Food and Drug Administration issued a warning about potential heart risks when combining two HIV drugs.

The agency said preliminary data suggest Roche’s Invirase and Abbott Laboratories’ Norvir can affect the electrical activity of the heart when used together. Changes to the heart’s electrical activity can delay the signals that trigger heart beats.

In some cases the problem can cause irregular heart rhythms, leading to lightheadedness, fainting, and even death.

The FDA made its announcement after reviewing data submitted by Roche about the heart activity of patients using its drug with Abbott’s Norvir. The agency said its review is ongoing and patients should not stop taking Invirase without talking to their doctor.

Doctors should review patients’ heart health and current medications to determine if they should continue taking Invirase, the agency said in a statement posted online.

Invirase was approved in 1995 and is marketed by Genentech, the biotech unit of Swiss drugmaker Roche.

The drug is used in combination with Norvir and other anti-viral drugs to control HIV in adults. Norvir is given at a low dose to boost the level of Invirase in the body.

The FDA previously asked Roche and all makers of protease inhibitor drugs, which include Invirase, to conduct studies of the heart side effects of their products.

A spokeswoman for Genentech said the company has submitted new drug labeling to Invirase that is under FDA review.

“The safety of patients is of the utmost importance to Genentech, and we continue to monitor and report to FDA adverse event reports from patients and physicians,” Tara Cooper said in a statement.

A spokeswoman for Abbott, based in North Chicago, Ill., said the language on heart rhythm risks already appears in Norvir’s labeling. The company previously completed the same studies FDA requested of Genentech, and updated its drug’s label in August 2008.

HIV attacks the body’s immune system, eventually causing AIDS. Just over 1.1 million Americans are estimated to have HIV and 232,000 do not know it, according to the Centers for Disease Control and Prevention.

The FDA issued the warning under its so-called early communication program, which seeks to alert the public to a potential side effect with a drug immediately, even if no direct link has been established.

Date: February 23, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE